Latest & greatest articles for thyroid

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on thyroid or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on thyroid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for thyroid

181. [Dose-Response Dependences for Frequency of RET/PTC Gene Rearrangements in Papillary Thyroid Carcinoma after Irradiation. Simple Pooling Analysis of Molecular Epidemiological Data]. (PubMed)

[Dose-Response Dependences for Frequency of RET/PTC Gene Rearrangements in Papillary Thyroid Carcinoma after Irradiation. Simple Pooling Analysis of Molecular Epidemiological Data]. On the basis of all possible publications on the theme included in the previously formed base of sources on molecular epidemiology of RET/PTC rearrangements in thyroid papillary carcinoma a pooled analysis ("simple pooling data") on determination of the dose-effect dependences for RET/PTC frequency in radiogenic (...) carcinomas of various irradiated groups was performed. (They are groups subjected to radiotherapeutic exposure, residents near the Chernobyl nuclear power plant (CNPP) and victims of nuclear bombing). The tendency to Pearson linear correlation (r = 0.746; p = 0.148) between the frequency of RET/PTC and the estimated dose on thyroid in the regions affected by the CNPP accident was revealed. But this tendency was recognized to be random owing to abnormally low values of the indicator for the most

2016 Radiatsionnaia biologiia, radioecologiia / Rossiĭskaia akademiia nauk

182. Thyroid cancer. (PubMed)

Thyroid cancer. Thyroid cancer is the fifth most common cancer in women in the USA, and an estimated over 62 000 new cases occurred in men and women in 2015. The incidence continues to rise worldwide. Differentiated thyroid cancer is the most frequent subtype of thyroid cancer and in most patients the standard treatment (surgery followed by either radioactive iodine or observation) is effective. Patients with other, more rare subtypes of thyroid cancer-medullary and anaplastic-are ideally (...) treated by physicians with experience managing these malignancies. Targeted treatments that are approved for differentiated and medullary thyroid cancers have prolonged progression-free survival, but these drugs are not curative and therefore are reserved for patients with progressive or symptomatic disease.Copyright © 2016 Elsevier Ltd. All rights reserved.

2016 Lancet

183. Neutron radiation therapy for advanced thyroid cancers (PubMed)

Neutron radiation therapy for advanced thyroid cancers The aim of this study was to review institutional outcomes for advanced thyroid cancers treated with fast neutron radiation therapy (FNRT) and photon radiation therapy (RT).In all, 62 consecutive patients were analyzed. Fifty-nine had stage IV disease. Twenty-three were treated with FNRT and 39 with photon RT. Median follow-up was 14 months. The primary endpoint was overall survival (OS).There was no significant difference in median OS

Full Text available with Trip Pro

2016 Advances in radiation oncology

184. Can New Ultrasound Signs Help in Identifying Follicular Variant of Papillary Carcinoma of Thyroid? – A Pilot Study (PubMed)

Can New Ultrasound Signs Help in Identifying Follicular Variant of Papillary Carcinoma of Thyroid? – A Pilot Study To describe two new ultrasound signs for thyroid nodules - "nodule in nodule" and "hypoechoic internal septae" and assess their usefulness in differentiating follicular variant of papillary thyroid carcinoma (FVPTC) from benign thyroid nodules (BTN).Ultrasound findings of 210 patients with histopathologically proven FVPTC (68 nodules, M:F=13:47 with mean age of 39.5±11.9 years

Full Text available with Trip Pro

2016 Ultrasound international open

185. Management of thyroid disease in pregnancy – Room for improvement in the first trimester (PubMed)

Management of thyroid disease in pregnancy – Room for improvement in the first trimester First-trimester care of maternal thyroid dysfunction has previously been shown to be poor. This study evaluates early management of thyroid dysfunction in pregnancy in Australia.Patients reviewed by the Obstetric Medicine team for thyroid dysfunction from 1 January 2012 to 30 June 2013 were included. Data were collected on gestation at referral from the patient's general practitioner to the antenatal (...) clinic, information provided in the referral letter, thyroid function tests and thyroid medications.Eighty-five women were included in the study. At the time of general practitioner referral to antenatal services, 19% of women with preexisting thyroid disease had no thyroid function tested. Forty-three percent had an abnormal thyroid-stimulating hormone defined as being outside the laboratory-specific pregnancy reference range if available, or outside the level of 0.1-2.5 mIu/L in the first trimester

Full Text available with Trip Pro

2016 Obstetric medicine

186. Selumetinib with radioactive iodine therapy for differentiated thyroid cancer - first line

Selumetinib with radioactive iodine therapy for differentiated thyroid cancer - first line Selumetinib with radioactive iodine therapy for differentiated thyroid cancer – first line Selumetinib with radioactive iodine therapy for differentiated thyroid cancer – first line NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Selumetinib (...) with radioactive iodine therapy for differentiated thyroid cancer – first line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions There are four different types of thyroid cancer, and the most common is known as differentiated thyroid cancer. It is a type of cancer which usually develops very slowly, and can often be cured by surgery. However, in a small number of patients the cancer then returns and becomes difficult to treat. Radioactive iodine

2016 Health Technology Assessment (HTA) Database.

187. Thyroid Nodules. (PubMed)

Thyroid Nodules. 27028927 2016 03 31 2018 12 02 1533-4406 374 13 2016 03 31 The New England journal of medicine N. Engl. J. Med. Thyroid Nodules. 1294-5 10.1056/NEJMc1600493 Burman Kenneth D KD Wartofsky Leonard L eng Letter Comment United States N Engl J Med 0255562 0028-4793 AIM IM N Engl J Med. 2015 Dec 10;373(24):2347-56 26650154 N Engl J Med. 2016 Mar 31;374(13):1294 27028928 N Engl J Med. 2016 Mar 31;374(13):1294 27028929 Female Humans Thyroid Nodule diagnosis 2016 3 31 6 0 2016 3 31 6 0

2016 NEJM

188. Thyroid Nodules. (PubMed)

Thyroid Nodules. 27028928 2016 03 31 2018 12 02 1533-4406 374 13 2016 03 31 The New England journal of medicine N. Engl. J. Med. Thyroid Nodules. 1294 10.1056/NEJMc1600493 Beano Abdallah M AM University of Jordan School of Medicine, Amman, Jordan baraaayman@gmail.com. Zmaili Mohammad A MA University of Jordan School of Medicine, Amman, Jordan baraaayman@gmail.com. Zayed Ayman A AA University of Jordan School of Medicine, Amman, Jordan baraaayman@gmail.com. eng Letter Comment United States N (...) Engl J Med 0255562 0028-4793 AIM IM N Engl J Med. 2015 Dec 10;373(24):2347-56 26650154 N Engl J Med. 2016 Mar 31;374(13):1294-5 27028927 Female Humans Thyroid Nodule diagnosis 2016 3 31 6 0 2016 3 31 6 0 2016 4 1 6 0 ppublish 27028928 10.1056/NEJMc1600493 10.1056/NEJMc1600493#SA1

Full Text available with Trip Pro

2016 NEJM

189. Thyroid Nodules. (PubMed)

Thyroid Nodules. 27028929 2016 03 31 2018 12 02 1533-4406 374 13 2016 03 31 The New England journal of medicine N. Engl. J. Med. Thyroid Nodules. 1294 10.1056/NEJMc1600493 Seidenwurm David D Sutter Medical Group, Sacramento, CA breslaj@sutterhealth.org. Breslau Jonathan J Sutter Medical Group, Sacramento, CA breslaj@sutterhealth.org. eng Letter Comment United States N Engl J Med 0255562 0028-4793 AIM IM N Engl J Med. 2015 Dec 10;373(24):2347-56 26650154 N Engl J Med. 2016 Mar 31;374(13):1294-5 (...) 27028927 Female Humans Thyroid Nodule diagnosis 2016 3 31 6 0 2016 3 31 6 0 2016 4 1 6 0 ppublish 27028929 10.1056/NEJMc1600493 10.1056/NEJMc1600493#SA2

Full Text available with Trip Pro

2016 NEJM

190. Guidance on the reporting of thyroid cytology specimens

Guidance on the reporting of thyroid cytology specimens CEff 200116 1 V5 Final Guidance on the reporting of thyroid cytology specimens January 2016 Authors: Dr Paul Cross, Gateshead Health NHS Foundation Trust (Chair) Dr Ashish Chandra, Guys and St Thomas’s NHS Foundation Trust Dr Thomas Giles, Royal Liverpool and Broadgreen University Hospitals NHS Trust Dr Sarah Johnson, Newcastle upon Tyne Hospitals NHS Foundation Trust Dr Gabrijela Kocjan, University College London Hospitals NHS Foundation (...) Trust Dr David Poller, Portsmouth Hospitals NHS Trust Professor Tim Stephenson, Sheffield Teaching Hospitals NHS Foundation Trust Unique document number G089 Document name Guidance on the reporting of thyroid cytology specimens Version number 2 Produced by Dr P Cross (Chair), Dr A Chandra, Dr T Giles, Dr S Johnson, Dr G Kocjan, Dr D Poller and Professor T Stephenson. The authors are all consultant cellular pathologists, reporting thyroid histology and/or cytology, some of whom hold or have held

2016 Royal College of Pathologists

191. Guidance on the reporting of thyroid cytology specimens

Guidance on the reporting of thyroid cytology specimens CEff 200116 1 V5 Final Guidance on the reporting of thyroid cytology specimens January 2016 Authors: Dr Paul Cross, Gateshead Health NHS Foundation Trust (Chair) Dr Ashish Chandra, Guys and St Thomas’s NHS Foundation Trust Dr Thomas Giles, Royal Liverpool and Broadgreen University Hospitals NHS Trust Dr Sarah Johnson, Newcastle upon Tyne Hospitals NHS Foundation Trust Dr Gabrijela Kocjan, University College London Hospitals NHS Foundation (...) Trust Dr David Poller, Portsmouth Hospitals NHS Trust Professor Tim Stephenson, Sheffield Teaching Hospitals NHS Foundation Trust Unique document number G089 Document name Guidance on the reporting of thyroid cytology specimens Version number 2 Produced by Dr P Cross (Chair), Dr A Chandra, Dr T Giles, Dr S Johnson, Dr G Kocjan, Dr D Poller and Professor T Stephenson. The authors are all consultant cellular pathologists, reporting thyroid histology and/or cytology, some of whom hold or have held

2016 Royal College of Pathologists

192. AACE/ACE/AME Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules

AACE/ACE/AME Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules ENDOCRINE PRACTICE Vol 22 (Suppl 1) May 2016 1 AACE/ACE/AME Guidelines AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ASSOCIAZIONE MEDICI ENDOCRINOLOGI MEDICAL GUIDELINES FOR CLINICAL PRACTICE FOR THE DIAGNOSIS AND MANAGEMENT OF THYROID NODULES – 2016 UPDATE APPENDIX Hossein Gharib, MD, MACP , MACE 1 , Co-Chair; Enrico Papini, MD, FACE 2 , Co-Chair (...) ; Jeffrey R. Garber, MD, FACP , FACE 3 ; Daniel S. Duick, MD, FACP , FACE 4 ; R. Mack Harrell, MD, FACP , FACE, ECNU 5 ; Laszlo Hegedüs, MD 6 ; Ralf Paschke, MD 7 ; Roberto Valcavi, MD, FACE 8 ; Paolo Vitti, MD 9 ; on behalf of the AACE/ACE/AME Task Force on Thyroid Nodules* American Association of Clinical Endocrinologists (AACE), American College of Endocrinology (ACE) and Associazione Medici Endocrinologi (AME) Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid

2016 American Association of Clinical Endocrinologists

193. Thyroid Nodules. (PubMed)

Thyroid Nodules. 26650154 2016 01 12 2016 11 26 1533-4406 373 24 2015 Dec 10 The New England journal of medicine N. Engl. J. Med. CLINICAL PRACTICE. Thyroid Nodules. 2347-56 10.1056/NEJMcp1415786 Burman Kenneth D KD Wartofsky Leonard L eng Journal Article Review United States N Engl J Med 0255562 0028-4793 9002-71-5 Thyrotropin AIM IM N Engl J Med. 2016 Mar 31;374(13):1294-5 27028927 N Engl J Med. 2016 Mar 31;374(13):1294 27028928 N Engl J Med. 2016 Mar 31;374(13):1294 27028929 Adult Algorithms (...) Biopsy, Fine-Needle Female Humans Practice Guidelines as Topic Thyroid Nodule diagnosis diagnostic imaging pathology therapy Thyroidectomy Thyrotropin blood Ultrasonography 2015 12 10 6 0 2015 12 10 6 0 2016 1 13 6 0 ppublish 26650154 10.1056/NEJMcp1415786

2015 NEJM

194. South Korea's Thyroid-Cancer "Epidemic" - Turning the Tide. (PubMed)

South Korea's Thyroid-Cancer "Epidemic" - Turning the Tide. 26650173 2016 01 12 2019 02 21 1533-4406 373 24 2015 Dec 10 The New England journal of medicine N. Engl. J. Med. South Korea's Thyroid-Cancer "Epidemic"--Turning the Tide. 2389-90 10.1056/NEJMc1507622 Ahn Hyeong Sik HS Korea University, Seoul, South Korea ahnhs@korea.ac.kr. Welch H Gilbert HG eng Letter United States N Engl J Med 0255562 0028-4793 AIM IM Carcinoma diagnostic imaging epidemiology Carcinoma, Papillary Epidemics (...) Guidelines as Topic Humans Mass Screening economics statistics & numerical data Medical Overuse trends Republic of Korea epidemiology Thyroid Cancer, Papillary Thyroid Neoplasms diagnostic imaging epidemiology surgery Ultrasonography 2015 12 10 6 0 2015 12 10 6 0 2016 1 13 6 0 ppublish 26650173 10.1056/NEJMc1507622

2015 NEJM

195. Thyroid surgery for Graves' disease and Graves' ophthalmopathy. (PubMed)

Thyroid surgery for Graves' disease and Graves' ophthalmopathy. Graves' disease is an autoimmune disease caused by the production of auto-antibodies against the thyroid-stimulating hormone receptor, which stimulates follicular cell production of thyroid hormone. It is the commonest cause of hyperthyroidism and may cause considerable morbidity with increased risk of cardiovascular and respiratory adverse events. Five per cent of people with Graves' disease develop moderate to severe Graves (...) ' ophthalmopathy. Thyroid surgery for Graves' disease commonly falls into one of three categories: 1) total thyroidectomy, which aims to achieve complete macroscopic removal of thyroid tissue; 2) bilateral subtotal thyroidectomy, in which bilateral thyroid remnants are left; and 3) unilateral total and contralateral subtotal thyroidectomy, or the Dunhill procedure. Recent American Thyroid Association guidelines on treatment of Graves' hyperthyroidism emphasised the role of surgery as one of the first-line

2015 Cochrane

196. HABP2 Mutation and Nonmedullary Thyroid Cancer. (PubMed)

HABP2 Mutation and Nonmedullary Thyroid Cancer. 26581001 2015 11 23 2018 12 02 1533-4406 373 21 2015 11 19 The New England journal of medicine N. Engl. J. Med. HABP2 Mutation and Nonmedullary Thyroid Cancer. 2086-7 10.1056/NEJMc1511631 Gara Sudheer Kumar SK Kebebew Electron E eng Letter Comment United States N Engl J Med 0255562 0028-4793 EC 3.4.21.- Serine Endopeptidases AIM IM N Engl J Med. 2015 Jul 30;373(5):448-55 26222560 N Engl J Med. 2015 Nov 19;373(21):2084 26581002 N Engl J Med. 2015 (...) Nov 19;373(21):2086 26581005 N Engl J Med. 2015 Nov 19;373(21):2085-6 26581004 N Engl J Med. 2015 Nov 19;373(21):2084-5 26581003 Adenoma genetics Female Germ-Line Mutation Humans Male Neoplastic Syndromes, Hereditary genetics Serine Endopeptidases genetics Thyroid Neoplasms genetics 2015 11 19 6 0 2015 11 19 6 0 2015 12 15 6 0 ppublish 26581001 10.1056/NEJMc1511631 10.1056/NEJMc1511631#SA5

2015 NEJM

197. HABP2 Mutation and Nonmedullary Thyroid Cancer. (PubMed)

HABP2 Mutation and Nonmedullary Thyroid Cancer. 26581002 2015 11 23 2018 12 02 1533-4406 373 21 2015 11 19 The New England journal of medicine N. Engl. J. Med. HABP2 Mutation and Nonmedullary Thyroid Cancer. 2084 10.1056/NEJMc1511631 Zhao Ximeng X Li Xiaoyi X Zhang Xue X eng Letter Comment United States N Engl J Med 0255562 0028-4793 EC 3.4.21.- Serine Endopeptidases AIM IM N Engl J Med. 2015 Jul 30;373(5):448-55 26222560 N Engl J Med. 2015 Nov 19;373(21):2086-7 26581001 Adenoma genetics Female (...) Germ-Line Mutation Humans Male Neoplastic Syndromes, Hereditary genetics Serine Endopeptidases genetics Thyroid Neoplasms genetics 2015 11 19 6 0 2015 11 19 6 0 2015 12 15 6 0 ppublish 26581002 10.1056/NEJMc1511631 10.1056/NEJMc1511631#SA1

Full Text available with Trip Pro

2015 NEJM

198. HABP2 Mutation and Nonmedullary Thyroid Cancer. (PubMed)

HABP2 Mutation and Nonmedullary Thyroid Cancer. 26581003 2015 11 23 2018 12 02 1533-4406 373 21 2015 11 19 The New England journal of medicine N. Engl. J. Med. HABP2 Mutation and Nonmedullary Thyroid Cancer. 2084-5 10.1056/NEJMc1511631 Zhou E Yihui EY Lin Zhimiao Z Yang Yong Y eng Letter Comment United States N Engl J Med 0255562 0028-4793 EC 3.4.21.- Serine Endopeptidases AIM IM N Engl J Med. 2015 Jul 30;373(5):448-55 26222560 N Engl J Med. 2015 Nov 19;373(21):2086-7 26581001 Adenoma genetics (...) Female Germ-Line Mutation Humans Male Neoplastic Syndromes, Hereditary genetics Serine Endopeptidases genetics Thyroid Neoplasms genetics 2015 11 19 6 0 2015 11 19 6 0 2015 12 15 6 0 ppublish 26581003 10.1056/NEJMc1511631 10.1056/NEJMc1511631#SA2

Full Text available with Trip Pro

2015 NEJM

199. HABP2 Mutation and Nonmedullary Thyroid Cancer. (PubMed)

HABP2 Mutation and Nonmedullary Thyroid Cancer. 26581004 2015 11 23 2018 12 02 1533-4406 373 21 2015 11 19 The New England journal of medicine N. Engl. J. Med. HABP2 Mutation and Nonmedullary Thyroid Cancer. 2085-6 10.1056/NEJMc1511631 Sponziello Marialuisa M Durante Cosimo C Filetti Sebastiano S eng Letter Comment United States N Engl J Med 0255562 0028-4793 EC 3.4.21.- Serine Endopeptidases AIM IM N Engl J Med. 2015 Jul 30;373(5):448-55 26222560 N Engl J Med. 2015 Nov 19;373(21):2086-7 (...) 26581001 Adenoma genetics Female Germ-Line Mutation Humans Male Neoplastic Syndromes, Hereditary genetics Serine Endopeptidases genetics Thyroid Neoplasms genetics 2015 11 19 6 0 2015 11 19 6 0 2015 12 15 6 0 ppublish 26581004 10.1056/NEJMc1511631 10.1056/NEJMc1511631#SA3

Full Text available with Trip Pro

2015 NEJM

200. HABP2 Mutation and Nonmedullary Thyroid Cancer. (PubMed)

HABP2 Mutation and Nonmedullary Thyroid Cancer. 26581005 2015 11 23 2018 12 02 1533-4406 373 21 2015 11 19 The New England journal of medicine N. Engl. J. Med. HABP2 Mutation and Nonmedullary Thyroid Cancer. 2086 10.1056/NEJMc1511631 Tomsic Jerneja J He Huiling H de la Chapelle Albert A eng P50 CA168505 CA NCI NIH HHS United States Letter Comment United States N Engl J Med 0255562 0028-4793 EC 3.4.21.- Serine Endopeptidases AIM IM N Engl J Med. 2015 Jul 30;373(5):448-55 26222560 N Engl J Med (...) . 2015 Nov 19;373(21):2086-7 26581001 Adenoma genetics Female Germ-Line Mutation Humans Male Neoplastic Syndromes, Hereditary genetics Serine Endopeptidases genetics Thyroid Neoplasms genetics 2015 11 19 6 0 2015 11 19 6 0 2015 12 15 6 0 ppublish 26581005 10.1056/NEJMc1511631 10.1056/NEJMc1511631#SA4

Full Text available with Trip Pro

2015 NEJM